The Prostate Health Education Network: Prostate Health Education and Awareness

Clinical Trials
Recurrent Prostate Cancer

Clinical trials for patients who have a recurrence of prostate cancer following primary treatment with surgery or radiation. These patients have not yet begun treatment with androgen deprivation therapy. This Information is provided to help patients identify clinical trials for educational purposes and not to recruit patients for any specific trials. Patients should consult with their personal doctor and the trial sponsors for additional information on trials of interest.

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer Number: NCT00588185 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Patients Receiving High-Dose Rate Brachytherapy Number: NCT00924027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy Number: NCT00969111 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of Modifications to Radical Prostatectomy Number: NCT01407263 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial Number: NCT01411345 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): University of Miami Sponsor Trial Information Trial Location(s) and Contact(s):
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Number: NCT01492972 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Proton Collaborative Group Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Number: NCT01581749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Albert DeNittis\|Main Line Health Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Number: NCT01581749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Albert DeNittis\|Main Line Health Sponsor Trial Information Trial Location(s) and Contact(s):	MRI for Assessing Prostate Cancer Response Number: NCT01607008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
MR-Guided Cryoablation of Prostate Bed Recurrences Number: NCT01727284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer Number: NCT01794403 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Number: NCT01802346 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Number: NCT01802346 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer Number: NCT01913106 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): The Methodist Hospital Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer Number: NCT01985828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer Number: NCT01985828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer Number: NCT02016248 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer Number: NCT02040610 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer Number: NCT02040610 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy Number: NCT02064673 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): yair lotan\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer Number: NCT02282137 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ebrahim Delpassand\|Radiomedix, Inc.\|Excel Diagnostics and Nuclear Oncology Center\|Radio Isotope Therapy of America Sponsor Trial Information Trial Location(s) and Contact(s):	Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy Number: NCT02307058 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer Number: NCT02334579 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer Number: NCT02334579 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer Number: NCT02420977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Number: NCT02452008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Number: NCT02452008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Number: NCT02465060 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can Number: NCT02484404 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can Number: NCT02484404 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Number: NCT02555189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Novartis\|Prostate Cancer Clinical Trials Consortium\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):	Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Number: NCT02555189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Novartis\|Prostate Cancer Clinical Trials Consortium\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors Number: NCT02600156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors Number: NCT02600156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer Number: NCT02635672 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Vincerx Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer Number: NCT02635672 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Vincerx Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer Number: NCT02643667 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Washington University School of Medicine\|Pharmacyclics LLC. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Number: NCT02649790 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Karyopharm Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Number: NCT02717156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Southern California\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Number: NCT02717156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Southern California\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Number: NCT02744287 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bellicum Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Number: NCT02744287 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bellicum Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer Number: NCT02766543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Number: NCT02769962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Number: NCT02769962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Number: NCT02826382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Number: NCT02826382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Number: NCT02861573 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer Number: NCT02933255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer Number: NCT02933255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Number: NCT02935205 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Mamta Parikh\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s):	Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Number: NCT02935205 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Mamta Parikh\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy Number: NCT02946996 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s):	Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Number: NCT02949284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Number: NCT02960022 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Astellas Pharma Global Development, Inc.\|Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):	Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Number: NCT03012321 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Northwestern University\|AstraZeneca\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Number: NCT03012321 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Northwestern University\|AstraZeneca\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s):
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s):	Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System Number: NCT03067051 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer Number: NCT03073395 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer Number: NCT03073395 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer Number: NCT03085043 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA Number: NCT03087903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer Number: NCT03089203 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Pennsylvania Sponsor Trial Information Trial Location(s) and Contact(s):	A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide� Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Number: NCT03129139 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Minneamrita Therapeutics LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide� Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Number: NCT03129139 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Minneamrita Therapeutics LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):	PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Number: NCT03232164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Wisconsin, Madison Sponsor Trial Information Trial Location(s) and Contact(s):
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Number: NCT03232164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Wisconsin, Madison Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy Number: NCT03253744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Cisplatin in Castration Resistant Prostate Cancer Number: NCT03275857 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Rochester\|Roswell Park Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy Number: NCT03312972 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Loyola University Sponsor Trial Information Trial Location(s) and Contact(s):
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Number: NCT03315871 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Number: NCT03317392 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Number: NCT03317392 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Number: NCT03333616 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Number: NCT03361735 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Number: NCT03361735 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy Number: NCT03388619 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy Number: NCT03388619 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer Number: NCT03392181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Northwestern University\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	PET/MRI for the Staging of Newly Diagnosed Prostate Cancer Number: NCT03392181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Northwestern University\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer Number: NCT03392181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Northwestern University\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Number: NCT03413995 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Clovis Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Number: NCT03419234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	The "PC-LIGHT" Study Number: NCT03419585 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy Number: NCT03424850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Washington University School of Medicine Sponsor Trial Information Trial Location(s) and Contact(s):	Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma Number: NCT03436654 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females Number: NCT03436745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Number: NCT03437941 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Corcept Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Number: NCT03437941 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Corcept Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Number: NCT03456843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Yale University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Number: NCT03456843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Yale University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy Number: NCT03458234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
Ultra-hypofractionated Radiation in Prostate Cancer Number: NCT03486821 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Ultra-hypofractionated Radiation in Prostate Cancer Number: NCT03486821 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Number: NCT03493945 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Number: NCT03493945 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores Number: NCT03495427 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy Number: NCT03496805 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences Sponsor Trial Information Trial Location(s) and Contact(s):
Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) Number: NCT03503344 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Francisco\|Janssen Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Number: NCT03507608 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Number: NCT03507608 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):	Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Number: NCT03507608 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) Number: NCT03525262 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Texas Southwestern Medical Center\|Boston Scientific Corporation Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) Number: NCT03525262 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Texas Southwestern Medical Center\|Boston Scientific Corporation Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery Number: NCT03541928 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The Methodist Hospital Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Number: NCT03543189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):
BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy Number: NCT03553602 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Loyola University Sponsor Trial Information Trial Location(s) and Contact(s):	Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Number: NCT03556228 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): VM Oncology, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Number: NCT03556228 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): VM Oncology, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Number: NCT03556228 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): VM Oncology, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study to Evaluate CCS1477 in Advanced Tumours Number: NCT03568656 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): CellCentric Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients Number: NCT03569280 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Kangpu Biopharmaceuticals, Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients Number: NCT03569280 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Kangpu Biopharmaceuticals, Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Number: NCT03574571 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Number: NCT03574571 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy Number: NCT03580499 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Number: NCT03582475 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy Number: NCT03585660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors Number: NCT03592264 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): OBI Pharma, Inc Sponsor Trial Information Trial Location(s) and Contact(s):	A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors Number: NCT03592264 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): OBI Pharma, Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy Number: NCT03619655 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer Number: NCT03624660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Number: NCT03637543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Beth Israel Deaconess Medical Center\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation Number: NCT03657108 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation Number: NCT03657108 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) Number: NCT03663218 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) Number: NCT03663218 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Number: NCT03674814 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Chicago\|Corcept Therapeutics\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Number: NCT03678025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Southwest Oncology Group\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance Number: NCT03679260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer Number: NCT03697148 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer Number: NCT03697148 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	4-aminopyridine Treatment for Nerve Injury Number: NCT03701581 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): University of Rochester\|Milton S. Hershey Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Number: NCT03706365 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):	Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency Number: NCT03716739 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|National Institute on Aging (NIA) Sponsor Trial Information Trial Location(s) and Contact(s):
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Number: NCT03725761 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|National Cancer Institute (NCI)\|Gilead Sciences Sponsor Trial Information Trial Location(s) and Contact(s):	Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Number: NCT03737370 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Tufts Medical Center\|Bayer\|Lahey Clinic\|Henry Ford Hospital\|Ohio State University Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Number: NCT03753243 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Mark Garzotto, MD\|Merck Sharp & Dohme LLC\|Astellas Pharma Inc\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Number: NCT03762759 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Emory University\|Telix International Pty Ltd\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Number: NCT03767244 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance Number: NCT03769766 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer Number: NCT03772834 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Number: NCT03775525 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Genzada Pharmaceuticals USA, Inc.\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Number: NCT03775525 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Genzada Pharmaceuticals USA, Inc.\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):	Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Number: NCT03777982 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Dana-Farber Cancer Institute\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Number: NCT03784677 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Number: NCT03784677 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Number: NCT03784677 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Number: NCT03796767 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s):
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer Number: NCT03802851 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer Number: NCT03808077 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer Number: NCT03808077 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery Number: NCT03809000 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): RTOG Foundation, Inc.\|Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Number: NCT03821246 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Lawrence Fong\|Genentech, Inc.\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Number: NCT03821792 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
CyberKnife Dose Escalation Prostate Cancer Trial Number: NCT03822494 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Number: NCT03824808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): University of Missouri-Columbia Sponsor Trial Information Trial Location(s) and Contact(s):	Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Number: NCT03824808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): University of Missouri-Columbia Sponsor Trial Information Trial Location(s) and Contact(s):
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Number: NCT03824808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): University of Missouri-Columbia Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer Number: NCT03833921 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Martha Mims\|Baylor College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Number: NCT03845166 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Number: NCT03850795 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Hinova Pharmaceuticals USA, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Number: NCT03850795 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Hinova Pharmaceuticals USA, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Number: NCT03866382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Number: NCT03866382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Number: NCT03873805 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Number: NCT03878524 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): OHSU Knight Cancer Institute\|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s):	Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors Number: NCT03880422 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT03888612 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT03888612 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Number: NCT03899467 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Suzhou Kintor Pharmaceutical Inc, Sponsor Trial Information Trial Location(s) and Contact(s):	the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Number: NCT03899467 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Suzhou Kintor Pharmaceutical Inc, Sponsor Trial Information Trial Location(s) and Contact(s):
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Number: NCT03899987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Roswell Park Cancer Institute\|AIM ImmunoTech Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Number: NCT03902951 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center\|Janssen Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. Number: NCT03910660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): BioXcel Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s):	CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone Number: NCT03934840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Masonic Cancer Center, University of Minnesota Sponsor Trial Information Trial Location(s) and Contact(s):
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone Number: NCT03934840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Masonic Cancer Center, University of Minnesota Sponsor Trial Information Trial Location(s) and Contact(s):	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Number: NCT03972657 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Number: NCT03972657 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Number: NCT03976843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients Number: NCT03987217 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Utah\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer Number: NCT03987386 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer Number: NCT04011410 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew C. James, MD\|University of Kentucky Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Number: NCT04019327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Number: NCT04019964 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):	INTREPId (INTermediate Risk Erection PreservatIon Trial) Number: NCT04025372 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Bayer\|Decipher Biosciences Sponsor Trial Information Trial Location(s) and Contact(s):
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Number: NCT04030559 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, Davis\|National Cancer Institute (NCI)\|Janssen, LP Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Number: NCT04032704 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Seagen Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Number: NCT04032704 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Seagen Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers Number: NCT04037358 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Number: NCT04038502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s):	Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Number: NCT04060394 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Laekna Limited Sponsor Trial Information Trial Location(s) and Contact(s):
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Number: NCT04060394 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Laekna Limited Sponsor Trial Information Trial Location(s) and Contact(s):	OPTimizing Treatment Focused Genetic Testing IN Cancer Number: NCT04066361 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy Number: NCT04068896 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): NGM Biopharmaceuticals, Inc Sponsor Trial Information Trial Location(s) and Contact(s):	Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormo Number: NCT04071236 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Number: NCT04090528 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|Merck Sharp & Dohme LLC\|Madison Vaccines, Inc\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):	pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Number: NCT04090528 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|Merck Sharp & Dohme LLC\|Madison Vaccines, Inc\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Number: NCT04100018 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Number: NCT04104776 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Constellation Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Number: NCT04104893 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Number: NCT04104893 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer Number: NCT04109729 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s):	Stereotactic Magnetic Resonance Guided Radiation Therapy Number: NCT04115254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Stereotactic Magnetic Resonance Guided Radiation Therapy Number: NCT04115254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Number: NCT04116775 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Julie Graff, MD\|Merck Sharp & Dohme LLC\|Prostate Cancer Foundation\|Johns Hopkins University\|Oregon Health and Science University\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Number: NCT04116775 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Julie Graff, MD\|Merck Sharp & Dohme LLC\|Prostate Cancer Foundation\|Johns Hopkins University\|Oregon Health and Science University\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described Number: NCT04122976 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s):
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Number: NCT04126070 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xiao X. Wei\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Number: NCT04134260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate Number: NCT04136353 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Sydney\|Australian and New Zealand Urogenital and Prostate Cancer Trials Group\|Bayer\|Cancer Trials Ireland\|Canadian Cancer Trials Group\|Memorial Sloan Kettering Cancer Center\|Prostate Cancer Clinical Trials Consortium Sponsor Trial Information Trial Location(s) and Contact(s):	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Number: NCT04140526 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): OncoC4, Inc.\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer Number: NCT04147806 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Albert Einstein College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s):	18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies Number: NCT04158245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Tulane University\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s):
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies Number: NCT04158245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Tulane University\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s):	The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer Number: NCT04167969 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Elucida Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Number: NCT04175431 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s):	CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy Number: NCT04179864 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Epizyme, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy Number: NCT04179864 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Epizyme, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer Number: NCT04179968 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Number: NCT04182516 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Nerviano Medical Sciences Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Number: NCT04182516 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Nerviano Medical Sciences Sponsor Trial Information Trial Location(s) and Contact(s):
Serial MRI Scans During Radiation Therapy Number: NCT04188535 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Radium-223 in Biochemically Recurrent Prostate Cancer Number: NCT04206319 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Radium-223 in Biochemically Recurrent Prostate Cancer Number: NCT04206319 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Number: NCT04207255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Number: NCT04207255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer Number: NCT04220983 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer Number: NCT04220983 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Number: NCT04221542 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s):
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s):	TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s):
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Number: NCT04249947 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Poseida Therapeutics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer Number: NCT04253483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Number: NCT04262154 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft Number: NCT04263025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft Number: NCT04263025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer Number: NCT04267887 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): OHSU Knight Cancer Institute\|Janssen Scientific Affairs, LLC\|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s):
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer Number: NCT04267939 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Number: NCT04288687 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Abramson Cancer Center of the University of Pennsylvania Sponsor Trial Information Trial Location(s) and Contact(s):
PK and Dose Escalation and Expansion Study of DST-2970 Number: NCT04291664 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): DisperSol Technologies, LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):	PK and Dose Escalation and Expansion Study of DST-2970 Number: NCT04291664 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): DisperSol Technologies, LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer Number: NCT04298983 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Clinical Trial of Green Tea Catechins in Men on Active Surveillance Number: NCT04300855 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer Number: NCT04301414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Matthew Dallos\|Bristol-Myers Squibb\|Ferring Pharmaceuticals\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s):	Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer Number: NCT04301414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Matthew Dallos\|Bristol-Myers Squibb\|Ferring Pharmaceuticals\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer Number: NCT04318028 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Number: NCT04335682 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance Foundation Trials, LLC.\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Number: NCT04335682 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance Foundation Trials, LLC.\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load Number: NCT04336943 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Number: NCT04337580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Number: NCT04337580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer Number: NCT04346225 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|National Cancer Institute (NCI)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Number: NCT04363164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|United States Department of Defense Sponsor Trial Information Trial Location(s) and Contact(s):	Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Number: NCT04363164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|United States Department of Defense Sponsor Trial Information Trial Location(s) and Contact(s):
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years Number: NCT04373564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Guerbet\|Bayer AG (Sponsor)\|Bracco (Sponsor)\|GEHC (Sponsor) Sponsor Trial Information Trial Location(s) and Contact(s):	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Number: NCT04381832 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arcus Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Number: NCT04381832 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arcus Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Number: NCT04383210 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Elevation Oncology Sponsor Trial Information Trial Location(s) and Contact(s):
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Number: NCT04388852 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer Number: NCT04390880 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Greater Los Angeles Healthcare System Sponsor Trial Information Trial Location(s) and Contact(s):
The Impact of Low Pressure Pneumo in RARP II Number: NCT04394676 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer Number: NCT04396808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer Number: NCT04402151 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer Number: NCT04421222 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ESSA Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks Number: NCT04422132 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Viewray Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Number: NCT04423029 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging Number: NCT04423211 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer Number: NCT04428788 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Celgene Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Number: NCT04446117 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Exelixis\|Roche-Genentech\|Takeda Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Number: NCT04446117 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Exelixis\|Roche-Genentech\|Takeda Sponsor Trial Information Trial Location(s) and Contact(s):
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Number: NCT04455750 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation Number: NCT04457232 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation Number: NCT04457232 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):	High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy Number: NCT04461509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alessandro D'Agnolo\|Progenics Pharmaceuticals, Inc.\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer Number: NCT04465500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Virginia Sponsor Trial Information Trial Location(s) and Contact(s):	EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer Number: NCT04465500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Virginia Sponsor Trial Information Trial Location(s) and Contact(s):
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy Number: NCT04471727 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Harpoon Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy Number: NCT04471727 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Harpoon Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Number: NCT04471974 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|Zenith Epigenetics\|Merck Sharp & Dohme LLC\|U.S. Army Medical Research and Development Command\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Number: NCT04471974 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|Zenith Epigenetics\|Merck Sharp & Dohme LLC\|U.S. Army Medical Research and Development Command\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) Number: NCT04477512 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Washington University School of Medicine\|Bristol-Myers Squibb\|Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Number: NCT04478279 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sapience Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Number: NCT04478279 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sapience Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer Number: NCT04483414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Number: NCT04484818 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers Number: NCT04485013 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Tizona Therapeutics, Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Number: NCT04486755 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):	Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Number: NCT04486755 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Number: NCT04486755 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):	Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency Number: NCT04493853 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Number: NCT04497844 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies Number: NCT04503265 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AtlasMedx, Incorporated Sponsor Trial Information Trial Location(s) and Contact(s):
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC Number: NCT04506567 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Number: NCT04513717 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Number: NCT04513717 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Number: NCT04514484 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Number: NCT04514484 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA Number: NCT04519879 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA Number: NCT04519879 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Number: NCT04521686 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Eli Lilly and Company\|Loxo Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Number: NCT04521686 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Eli Lilly and Company\|Loxo Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer Number: NCT04528199 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|FutureChem Sponsor Trial Information Trial Location(s) and Contact(s):
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer Number: NCT04528199 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|FutureChem Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Jump: MR Simulation For Radiation Therapy Master Protocol Number: NCT04545957 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Jump: MR Simulation For Radiation Therapy Master Protocol Number: NCT04545957 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Number: NCT04550494 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer Number: NCT04552509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer Number: NCT04552509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants Number: NCT04557059 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Number: NCT04557449 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Number: NCT04564027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Number: NCT04564027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate Imaging Using MRI +/- Contrast Enhancement Number: NCT04571840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Prostate Imaging Using MRI +/- Contrast Enhancement Number: NCT04571840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of FT-7051 in Men With MCRPC Number: NCT04575766 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Forma Therapeutics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Re-treatment 225Ac-J591 for mCRPC Number: NCT04576871 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Number: NCT04580485 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Incyte Corporation Sponsor Trial Information Trial Location(s) and Contact(s):
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Number: NCT04586335 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Haihe Biopharma Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Number: NCT04586335 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Haihe Biopharma Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Number: NCT04592237 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Janssen Pharmaceutica Sponsor Trial Information Trial Location(s) and Contact(s):	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Number: NCT04592237 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Janssen Pharmaceutica Sponsor Trial Information Trial Location(s) and Contact(s):
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Number: NCT04597359 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Number: NCT04597359 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Number: NCT04597359 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study of PF-07248144 in Advanced or Metastatic Solid Tumors Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
Study of PF-07248144 in Advanced or Metastatic Solid Tumors Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	Study of PF-07248144 in Advanced or Metastatic Solid Tumors Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial Number: NCT04624256 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of CC-90011 and Comparators in Participants With Prostate Cancer Number: NCT04628988 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Celgene Sponsor Trial Information Trial Location(s) and Contact(s):
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Number: NCT04631744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer Number: NCT04633252 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer Number: NCT04633252 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer Number: NCT04635059 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical College of Wisconsin Sponsor Trial Information Trial Location(s) and Contact(s):
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer Number: NCT04644770 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence Number: NCT04645810 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Rochester Sponsor Trial Information Trial Location(s) and Contact(s):	Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy Number: NCT04646434 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy Number: NCT04646434 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment Number: NCT04647526 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): POINT Biopharma Sponsor Trial Information Trial Location(s) and Contact(s):
Preliminary Effectiveness of Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Intermediate Risk Prostate Cancer Number: NCT04656678 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Insulin Resistance Following ADT for Prostate CA Number: NCT04658849 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s):
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Number: NCT04660929 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Carisma Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s):	ARX517 in Subjects With Advanced Solid Tumor Number: NCT04662580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ambrx, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
ARX517 in Subjects With Advanced Solid Tumor Number: NCT04662580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ambrx, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	ARX517 in Subjects With Advanced Solid Tumor Number: NCT04662580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ambrx, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s):	Study of PCUR-101 in Combination With ADT in Patients With mCRPC Number: NCT04677855 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer Number: NCT04689828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Novartis Pharmaceuticals\|Novartis Sponsor Trial Information Trial Location(s) and Contact(s):	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resist Number: NCT04691804 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Jiangsu HengRui Medicine Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer Number: NCT04692675 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial Number: NCT04693377 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Single-Port Versus Multi-Port Robotic Radical Prostatectomy Number: NCT04696263 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging Number: NCT04698564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging Number: NCT04698564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):	Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging Number: NCT04698564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s):	PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer Number: NCT04702737 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s):	Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Number: NCT04703920 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Michigan Rogel Cancer Center\|Pfizer\|Acrotech Biopharma LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Number: NCT04704505 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):	TH1902 in Patients With Advanced Solid Tumors Number: NCT04706962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Theratechnologies\|PPD Sponsor Trial Information Trial Location(s) and Contact(s):
TH1902 in Patients With Advanced Solid Tumors Number: NCT04706962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Theratechnologies\|PPD Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):	68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Number: NCT04716725 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Francisco\|Conquer Cancer Foundation\|Gateway for Cancer Research\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC Number: NCT04720157 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Novartis Pharmaceuticals\|Alliance Foundation Trials, LLC.\|RTOG Foundation, Inc.\|Novartis Sponsor Trial Information Trial Location(s) and Contact(s):	Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Number: NCT04726332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer Number: NCT04729114 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Propella Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer Number: NCT04729114 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Propella Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer Number: NCT04731844 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Rochester Sponsor Trial Information Trial Location(s) and Contact(s):
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma Number: NCT04740034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s):
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Number: NCT04742361 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ABX advanced biochemical compounds GmbH Sponsor Trial Information Trial Location(s) and Contact(s):	Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors Number: NCT04742959 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): TransThera Sciences (Nanjing), Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Number: NCT04748042 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Abemaciclib With or Without Atezolizumab for mCRPC Number: NCT04751929 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Eli Lilly and Company\|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT04754191 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Number: NCT04754425 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Number: NCT04768868 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Impact Therapeutics, Inc.\|Covance Sponsor Trial Information Trial Location(s) and Contact(s):
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Number: NCT04768868 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Impact Therapeutics, Inc.\|Covance Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer Number: NCT04787744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s):	Transperineal vs. Transrectal MRI-targeted Prostate Biopsy Number: NCT04815876 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Number: NCT04821622 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of Transperineal Biopsy Under Local Anesthesia Number: NCT04843566 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent Number: NCT04844749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Veru Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Number: NCT04846478 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Dana-Farber Cancer Institute\|Epizyme, Inc.\|Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Number: NCT04848337 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ulka Vaishampayan\|Merck Sharp & Dohme Corp.\|University of Michigan\|Hoosier Cancer Research Network Sponsor Trial Information Trial Location(s) and Contact(s):
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions Number: NCT04867603 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Norbert Avril, M.D.\|Case Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions Number: NCT04867603 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Norbert Avril, M.D.\|Case Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) Number: NCT04868604 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Clarity Pharmaceuticals Ltd Sponsor Trial Information Trial Location(s) and Contact(s):
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study Number: NCT04870515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study Number: NCT04870515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC Number: NCT04886986 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Weill Medical College of Cornell University\|POINT Biopharma Sponsor Trial Information Trial Location(s) and Contact(s):
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Number: NCT04890613 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Senhwa Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy Number: NCT04905069 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics Number: NCT04905082 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy Number: NCT04915508 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Number: NCT04925284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Number: NCT04925284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Number: NCT04926181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|Janssen Scientific Affairs, LLC\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer Number: NCT04927663 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Michael Evans\|U.S. Army Medical Research Acquisition Activity\|National Institute of Mental Health (NIMH)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)	11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer Number: NCT04927663 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Michael Evans\|U.S. Army Medical Research Acquisition Activity\|National Institute of Mental Health (NIMH)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer Number: NCT04927663 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Michael Evans\|U.S. Army Medical Research Acquisition Activity\|National Institute of Mental Health (NIMH)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)	Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors Number: NCT04931823 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Conjupro Biotherapeutics, Inc.\|CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer Number: NCT04943536 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Alessa Therapeutics Inc.\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma Number: NCT04945642 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma Number: NCT04945642 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC Number: NCT04946370 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Weill Medical College of Cornell University\|United States Department of Defense\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer Number: NCT04947254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma Number: NCT04951492 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Number: NCT04957290 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Noxopharm Limited Sponsor Trial Information Trial Location(s) and Contact(s):	Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue Number: NCT04972097 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Number: NCT04976257 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Ryan Kohlbrenner, MD\|Radiological Society of North America\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Number: NCT04976257 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Ryan Kohlbrenner, MD\|Radiological Society of North America\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer Number: NCT04978675 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging Number: NCT04981223 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer Number: NCT04981834 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer Number: NCT04984343 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Viewray Inc.\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer Number: NCT04984343 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Viewray Inc.\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer Number: NCT04985565 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Number: NCT04986423 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Zenith Epigenetics\|Astellas Pharma Inc\|Newsoara Biopharma Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Number: NCT04989946 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Wisconsin, Madison\|Madison Vaccines, Inc\|United States Department of Defense Sponsor Trial Information Trial Location(s) and Contact(s):
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness Number: NCT04995198 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Prostate Cancer Clinical Trials Consortium\|Memorial Sloan Kettering Cancer Center\|Fred Hutchinson Cancer Center\|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Advancing Cancer Treatment, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness Number: NCT04995198 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Prostate Cancer Clinical Trials Consortium\|Memorial Sloan Kettering Cancer Center\|Fred Hutchinson Cancer Center\|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Advancing Cancer Treatment, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Insulin Resistance and Androgen Deprivation Therapy Number: NCT04995978 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s):	Insulin Resistance and Androgen Deprivation Therapy Number: NCT04995978 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer Number: NCT04997018 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT05005728 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xencor, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. Number: NCT05010200 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ashutosh Kumar Tewari\|Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s):	The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. Number: NCT05010200 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ashutosh Kumar Tewari\|Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer Number: NCT05010759 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT05011188 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Rahul Aggarwal\|Fortis Therapeutics, Inc.\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers Number: NCT05011383 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Number: NCT05022849 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer Number: NCT05027477 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Number: NCT05032040 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xencor, Inc.\|ICON plc Sponsor Trial Information Trial Location(s) and Contact(s):
COAST Therapy in Advanced Solid Tumors and Prostate Cancer Number: NCT05036226 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s):	Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer Number: NCT05037500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Roswell Park Cancer Institute\|National Comprehensive Cancer Network Sponsor Trial Information Trial Location(s) and Contact(s):
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) Number: NCT05038332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) Number: NCT05043012 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Number: NCT05045066 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Mayo Clinic\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Number: NCT05045066 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Mayo Clinic\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Number: NCT05045066 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Mayo Clinic\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	KZR-261 in Subjects With Advanced Solid Malignancies Number: NCT05047536 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Kezar Life Sciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Number: NCT05050084 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Number: NCT05050084 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer Number: NCT05053152 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring Number: NCT05054296 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer Number: NCT05055843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer Number: NCT05055843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Number: NCT05059236 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT05067140 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study Number: NCT05067777 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC Number: NCT05075577 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): ESSA Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer Number: NCT05077098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Mark Stein\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s):	Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Number: NCT05081193 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Clarus Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Pioglitazone and Insulin Resistance in ADT Number: NCT05098327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): State University of New York at Buffalo Sponsor Trial Information Trial Location(s) and Contact(s):	Pioglitazone and Insulin Resistance in ADT Number: NCT05098327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): State University of New York at Buffalo Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer Number: NCT05100472 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Number: NCT05113537 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Vadim S Koshkin\|Prostate Cancer Foundation\|Eli Lilly and Company\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT05125016 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones Number: NCT05133440 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy Number: NCT05155046 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients Number: NCT05156372 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients Number: NCT05156372 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer Number: NCT05156905 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of PRT2527 in Patients With Advanced Solid Tumors Number: NCT05159518 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Prelude Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of PRT2527 in Patients With Advanced Solid Tumors Number: NCT05159518 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Prelude Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Number: NCT05160597 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Number: NCT05160597 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Number: NCT05160597 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Number: NCT05168618 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer Number: NCT05169684 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer Number: NCT05169970 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer Number: NCT05169970 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors Number: NCT05176483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Number: NCT05177042 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Number: NCT05189457 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|BeiGene Sponsor Trial Information Trial Location(s) and Contact(s):
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer Number: NCT05204927 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Curium US LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05215574 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05215574 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05215574 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). Number: NCT05219500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Excel Diagnostics and Nuclear Oncology Center Sponsor Trial Information Trial Location(s) and Contact(s):	Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). Number: NCT05219500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Excel Diagnostics and Nuclear Oncology Center Sponsor Trial Information Trial Location(s) and Contact(s):
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer Number: NCT05224869 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer Number: NCT05241613 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Accutar Biotechnology Inc Sponsor Trial Information Trial Location(s) and Contact(s):
PET Imaging Study of 89Zr-DFO-YS5 Number: NCT05245006 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Robert Flavell, MD, PhD\|United States Department of Defense\|Fortis Therapeutics, Inc.\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) Number: NCT05249127 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Clarity Pharmaceuticals Ltd Sponsor Trial Information Trial Location(s) and Contact(s):
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Number: NCT05252390 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Nuvation Bio Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors Number: NCT05268666 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Jubilant Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Number: NCT05288166 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Number: NCT05288166 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Number: NCT05293496 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): MacroGenics Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05311618 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05311618 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors Number: NCT05313191 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
RElugolix VErsus LeUprolide Cardiac Trial Number: NCT05320406 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy Number: NCT05324098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
An Imaging Agent (Perflutren Lipid Microspheres) With Ultrasound for Imaging of Prostate Cancer Number: NCT05336786 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):	Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) Number: NCT05345444 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) Number: NCT05348577 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Number: NCT05361798 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Number: NCT05361798 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care Number: NCT05366842 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Johns Hopkins University Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Number: NCT05369000 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Lava Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients Number: NCT05375539 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
PSMA-PET to Guide Prostatectomy Number: NCT05381103 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Five Eleven Pharma, Inc.\|Indiana University Sponsor Trial Information Trial Location(s) and Contact(s):	Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort Number: NCT05384535 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer Number: NCT05396872 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) Number: NCT05407311 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of ORIC-944 in Patients With Metastatic Prostate Cancer Number: NCT05413421 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ORIC Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Study of ORIC-944 in Patients With Metastatic Prostate Cancer Number: NCT05413421 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ORIC Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Study of ORIC-944 in Patients With Metastatic Prostate Cancer Number: NCT05413421 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ORIC Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection Number: NCT05413850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Blue Earth Therapeutics Ltd\|PSI CRO Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Number: NCT05415098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies Number: NCT05417594 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC) Number: NCT05424783 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC) Number: NCT05424783 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer Number: NCT05438563 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer Number: NCT05441501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer Number: NCT05454488 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Philanthropic Sources Sponsor Trial Information Trial Location(s) and Contact(s):	Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer Number: NCT05477823 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Number: NCT05479578 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Rashmi Verma, MD\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours Number: NCT05489211 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Number: NCT05489991 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Number: NCT05496959 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Number: NCT05519449 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	MGC018 Versus Androgen Receptor Axis-targeted Therapy in Participants With Metastatic Castration Resistant Prostate Cancer Number: NCT05551117 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors Number: NCT05585034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors Number: NCT05585034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers Number: NCT05588609 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):

Total: 623 Clinical Trials

PHEN,Inc. © 2024 All rights reserved